SFE Investment Counsel’s BioTelemetry, Inc. BEAT Stock Holding History

SFE Investment Counsel’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-11,335	Closed	-$817K	–	119
2020 Q4	$817K	Buy	11,335 +1,129	+11%	+$59.1K	0.26%	81
2020 Q3	$465K	Buy	10,206 +1,850	+22%	+$77.3K	0.19%	86
2020 Q2	$378K	Buy	+8,356	New	+$374K	0.17%	84
2020 Q1	–	Sell	-5,119	Closed	-$237K	–	113
2019 Q4	$237K	Hold	5,119	–	–	0.1%	105
2019 Q3	$208K	Buy	+5,119	New	+$221K	0.09%	113
2019 Q1	–	Sell	-8,962	Closed	-$535K	–	129
2018 Q4	$535K	Sell	8,962 -1,655	-16%	-$99.4K	0.27%	85
2018 Q3	$684K	Sell	10,617 -94	-0.9%	-$5.25K	0.26%	89
2018 Q2	$482K	Buy	+10,711	New	+$427K	0.2%	94

Other funds holding BEAT

LCM

Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return

SFE Investment Counsel's BEAT Position: Q1 2021 in Review

SFE Investment Counsel sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 11,335 shares — an estimated $817K sold.

SFE Investment Counsel first reported a position in BEAT in Q2 2018 and held it in 8 quarters. The position peaked at $817K in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

SFE Investment Counsel reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
SFE Investment Counsel sold 11,335 BioTelemetry, Inc. shares in Q1 2021, an estimated $817K.
SFE Investment Counsel first reported a position in BioTelemetry, Inc. in Q2 2018 and held it in 8 quarters.
SFE Investment Counsel's BioTelemetry, Inc. position peaked at $817K in Q4 2020.
1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on SFE Investment Counsel's 13F filing for Q1 2021, filed 30 Apr 2021.